Use of modified vaccinia virus strains in combination with a chemotherapeutic agent for use in therapeutic methods
First Claim
1. A method for treating one or more adverse side effects associated with viral treatment, comprising administering a chemotherapeutic agent to a subject treated with a therapeutic virus, wherein:
- the subject exhibits one or more adverse effects following administration of the virus;
the amount of chemotherapeutic agent administered is sufficient to control or reduce viral titer in the subject; and
whereby an adverse side effect is treated.
2 Assignments
0 Petitions
Accused Products
Abstract
Modified or attenuated therapeutic viruses in combination with a chemotherapeutic agent, and methods for administering therapeutic viruses in combination with a chemotherapeutic agent to a subject for controlling viral titer, are provided. The combination of a therapeutic virus and chemotherapeutic agent can be used in methods of treating diseases, such as proliferative and inflammatory disorders, including as anti-tumor agents. The combination can also be used as a preventive measure or as a treatment to reduce or eliminate symptoms associated with oncolytic viral therapy.
161 Citations
41 Claims
-
1. A method for treating one or more adverse side effects associated with viral treatment, comprising administering a chemotherapeutic agent to a subject treated with a therapeutic virus, wherein:
-
the subject exhibits one or more adverse effects following administration of the virus; the amount of chemotherapeutic agent administered is sufficient to control or reduce viral titer in the subject; and whereby an adverse side effect is treated. - View Dependent Claims (3, 4, 5, 6, 7, 8, 9, 11, 13, 14, 15, 16, 17, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)
-
-
2. A method for controlling viral load in a subject, comprising administering a chemotherapeutic agent to a subject treated with a therapeutic virus, wherein:
-
the subject exhibits a viral titer that is equal to or exceeds an amount that causes one or more adverse side effects in the subject during treatment with the virus; the amount of chemotherapeutic agent administered is sufficient to control or reduce viral titer in the subject. - View Dependent Claims (10, 12, 18)
-
-
30. A method to maintain or control numbers of a modified vaccinia virus delivered to a patient for treatment of cancer such that the patient suffers minimal adverse effects associated with the virus, comprising:
-
co-administration of the virus with a regimen of at least one chemotherapeutic agent selected from among gemcitabine, irinotecan, doxorubicin and cisplatin, wherein the amount of gemcitabine, irinotecan, doxorubicin or cisplatin administered is sufficient to control or reduce viral titer in the subject. - View Dependent Claims (31, 32, 33)
-
-
34. A combination, comprising:
-
a composition containing a therapeutic virus, wherein the virus is effective for treatment of cancer; and a composition containing a chemotherapeutic agent in an amount effective for clearing the virus from a subject, when the composition containing the chemotherapeutic agent is administered as a single dose. - View Dependent Claims (35, 36, 37, 38, 39, 40, 41)
-
Specification